|
related topics |
{property, intellectual, protect} |
{debt, indebtedness, cash} |
{product, market, service} |
{regulation, government, change} |
{acquisition, growth, future} |
{operation, international, foreign} |
{cost, regulation, environmental} |
{product, candidate, development} |
{customer, product, revenue} |
{system, service, information} |
{personnel, key, retain} |
{product, liability, claim} |
{condition, economic, financial} |
{cost, operation, labor} |
{regulation, change, law} |
{competitive, industry, competition} |
|
Risks Related to the Growth of Our Business
The Company must continually offer new products and services
The Company must be able to manufacture new and improved products to meet customer demand on a timely and cost-effective basis
The Company may not successfully integrate the Applied Biosystems business or realize all of the anticipated benefits of our merger with Applied Biosystems
The Company s future growth depends in part on our ability to acquire new products, services, and technologies through additional acquisitions, which may absorb significant resources and may not be successful
The Company may not successfully manage its current and future divestitures, and as a result, may not achieve some or all of the expected benefits of such divestitures
The Company faces significant competition
Consolidation trends in both our market and that of our customers have increased competition
Adverse conditions in the global economy and disruption of financial markets may significantly harm our revenue, profitability and results of operations
A significant portion of our sales are dependent upon our customers capital spending policies and research and development budgets, and government funding of research and development programs at universities and other organizations, which are subject to significant and unexpected decreases
Some of our customers are requiring us to change our sales arrangements to lower their costs which may limit our pricing flexibility and harm our business
Risks Related to the Development and Manufacturing of Our Products
Our business depends on our ability to license new technologies from others
Our business could be harmed if we lose rights to technologies that we have licensed from others
Violation of government regulations or voluntary quality programs could harm demand for our products or services
The Company relies on other companies for the manufacture of some of our products and also for the supply of some components of the products we manufacture on our own which may hinder our ability to satisfy customer demand
Risks Related to Our Operations
Loss of key personnel may adversely affect our business
We have substantial indebtedness, which could adversely affect our cash flows, business and financial condition
Our credit facilities contain restrictions that limit our flexibility in operating our business
The Company could incur more indebtedness, which may increase the risks associated with our substantial leverage, including our ability to service our indebtedness and pay dividends on our common stock
The Company could lose the tax deduction for interest expense associated with our convertible senior notes due in 2023, the convertible senior notes due in 2024 and the convertible senior notes due in 2025
Our federal, state and local income tax returns may, from time to time, be selected for audit by the taxing authorities, which may result in tax assessments or penalties
The Company s business, particularly the development and marketing of information-based products and services, depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, and Internet applications and related tools and functions
Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
Risks Related to Our International Operations
International unrest or foreign currency fluctuations could cause volatility in our international sales and our financial results.
Risks Related to Our Intellectual Property
The Company may not be able to effectively and efficiently protect and enforce our proprietary technology
The Company is currently, and could in the future be, subject to lawsuits, arbitrations, investigations, and other legal actions with private parties and governmental entities, particularly involving claims for infringement of patents and other intellectual property rights, and we may need to obtain licenses to intellectual property from others
Disclosure of trade secrets could cause harm to our business
Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and legal actions against them could harm our business
Risks Related to Environmental and Product Liability Issues
Risks related to handling of hazardous materials and other regulations governing environmental safety
Potential product liability claims could cause harm to our business
Full 10-K form ▸
|
|
related documents |
1073431--3/2/2009--Life_Technologies_Corp |
1073431--3/1/2006--INVITROGEN_CORP |
1107216--3/12/2008--ORCHID_CELLMARK_INC |
1107216--3/15/2007--ORCHID_CELLMARK_INC |
1342126--3/17/2008--Morgans_Hotel_Group_Co. |
1342126--3/16/2009--Morgans_Hotel_Group_Co. |
1145460--3/1/2007--INVERNESS_MEDICAL_INNOVATIONS_INC |
1145460--3/16/2006--INVERNESS_MEDICAL_INNOVATIONS_INC |
1107216--5/24/2006--ORCHID_CELLMARK_INC |
1261694--3/16/2006--TESSERA_TECHNOLOGIES_INC |
924717--12/11/2009--SURMODICS_INC |
1107216--3/16/2009--ORCHID_CELLMARK_INC |
924717--12/15/2008--SURMODICS_INC |
924717--12/14/2010--SURMODICS_INC |
1087294--3/19/2010--CUMBERLAND_PHARMACEUTICALS_INC |
1342126--3/31/2006--Morgans_Hotel_Group_Co. |
1145460--3/2/2009--INVERNESS_MEDICAL_INNOVATIONS_INC |
1342126--3/30/2007--Morgans_Hotel_Group_Co. |
1145460--2/29/2008--INVERNESS_MEDICAL_INNOVATIONS_INC |
706539--3/16/2006--CHIRON_CORP |
917273--2/26/2009--RAMBUS_INC |
1145460--3/1/2010--INVERNESS_MEDICAL_INNOVATIONS_INC |
945828--9/28/2010--AMERITYRE_CORP |
924642--4/1/2010--DIGITAL_ANGEL_CORP |
1318310--3/13/2008--ev3_Inc. |
1274563--4/15/2010--HELICOS_BIOSCIENCES_CORP |
865917--1/29/2010--VERSANT_CORP |
868368--12/10/2010--ROCHESTER_MEDICAL_CORPORATION |
720762--10/29/2010--NON_INVASIVE_MONITORING_SYSTEMS_INC_/FL/ |
1052595--3/11/2010--Red_Lion_Hotels_CORP |
|